Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Lexaria Bioscience (LEXX) over the last 15 years, with Q4 2025 value amounting to $16866.0.

  • Lexaria Bioscience's Depreciation & Amortization (CF) fell 4919.11% to $16866.0 in Q4 2025 from the same period last year, while for Nov 2025 it was $71496.0, marking a year-over-year decrease of 1126.23%. This contributed to the annual value of $87825.0 for FY2025, which is 1532.7% up from last year.
  • Per Lexaria Bioscience's latest filing, its Depreciation & Amortization (CF) stood at $16866.0 for Q4 2025, which was down 4919.11% from $21398.0 recorded in Q3 2025.
  • In the past 5 years, Lexaria Bioscience's Depreciation & Amortization (CF) ranged from a high of $70928.0 in Q3 2023 and a low of $2277.0 during Q1 2025
  • For the 5-year period, Lexaria Bioscience's Depreciation & Amortization (CF) averaged around $25637.4, with its median value being $24871.0 (2022).
  • In the last 5 years, Lexaria Bioscience's Depreciation & Amortization (CF) soared by 18678.63% in 2023 and then plummeted by 8570.71% in 2025.
  • Over the past 5 years, Lexaria Bioscience's Depreciation & Amortization (CF) (Quarter) stood at $27930.0 in 2021, then dropped by 11.46% to $24730.0 in 2022, then rose by 16.37% to $28778.0 in 2023, then grew by 15.35% to $33195.0 in 2024, then plummeted by 49.19% to $16866.0 in 2025.
  • Its Depreciation & Amortization (CF) stands at $16866.0 for Q4 2025, versus $21398.0 for Q3 2025 and $30955.0 for Q2 2025.